JNM Editors' Choice Awards: Johannes Czernin recognizes outstanding contributions to *JNM* in 2023, as selected for awards at the upcoming SNMMI Annual Meeting. . . . . ***Page 825***

Discussions with leaders: Frederik (Freek) J. Beekman, PhD, distinguished inventor, entrepreneur, and professor of Applied Physics at the Technische Universiteit Delft, talks with Czernin and Mona about his career in academia and industry. . . . . ***Page 826***

Amyloid-β, tau, and F-DOPA PET: Burkett and colleagues offer an educational overview of visual interpretation of amyloid, tau, and dopaminergic PET images; their roles in the clinical context; and potential pitfalls in interpretation. . . . . ***Page 829***

[18F]-FET PET cost-effectiveness: Rosen and colleagues report on [18F]-FET PET for treatment monitoring of multimodal therapy, including checkpoint inhibitors, targeted therapies, radiotherapy, and associated combinations, in patients with brain metastases secondary to melanoma or non–small cell lung cancer. . . . . ***Page 838***

PET/CT in oligometastatic breast cancer: Moser and colleagues assess the impact of [18F]-FDG PET/CT on the definition of oligometastatic disease and detection of metastatic patterns in breast cancer, emphasizing the importance of standardizing imaging definitions. . . . . ***Page 845***

Predictive metabolic response in TKI therapy: Schuler and colleagues evaluate metabolic response on [18F]-FDG PET after short-course osimertinib to identify lung cancer patients with resistance to epidermal growth factor receptor tyrosine kinase inhibitors who will benefit from next-line osimertinib. . . . . ***Page 851***

CLDN18.2 molecular imaging in cancer: Qi and colleagues detail a first-in-human study of [68Ga]-NC-BCH PET and its biodistribution, metabolism, dosimetry, safety, and potential for quantifying claudin-18 isoform 2 expression in gastrointestinal cancer patients. ***Page 856***

PET/MRI and methotrexate neurotoxicity: Baratto and colleagues use [18F]FDG PET/MRI to diagnose high-dose methotrexate–induced brain injury and correlate the results with cognitive impairment identified by neurocognitive testing in pediatric cancer survivors. . . . . ***Page 864***

[68Ga]-FAPI-46 in [18F]-FDG–negative lung cancer: Röhrich and colleagues evaluate in lung cancer patients the diagnostic potential of static and dynamic [68Ga]-FAPI-46 PET imaging in [18F]-FDG–negative pulmonary lesions. . . . . ***Page 872***

[68Ga]-FAPI PET and FAP-RPT in sarcoma: Lanzafame and colleagues describe the diagnostic performance and accuracy of [68Ga]-FAPI PET in patients with various bone and soft-tissue sarcomas, highlighting potential eligibility for FAP-targeted radiopharmaceutical therapy. . ***Page 880***

FAPI PET/CT in genitourinary cancers: Hagens and colleagues conduct a systematic analysis of current literature on the utility of FAPI PET/CT for staging patients with genitourinary malignancies. ***Page 888***

Novel [68Ga]-labeled PET/MRI in prostate cancer: Duan and colleagues assess in a phase II study the feasibility, safety, and diagnostic performance of [68Ga]-NeoB and [68Ga]-PSMA-R2 PET/MRI for detection of biochemically recurrent prostate cancer. . . . . ***Page 897***

PSMA PET/CT heterogeneity intensity score: Swiha and colleagues develop a simple, clinically applicable PSMA PET/CT score, encompassing the elements of SUV_{mean} without additional quantification, for use in predicting response to [177Lu]-PSMA therapy. ***Page 904***

Extended [177Lu]Lu-PSMA therapy: Seifert and colleagues investigate the safety and efficacy of extended [177Lu]Lu-PSMA radiopharmaceutical treatment in patients with metastatic castration-resistant prostate cancer who have received more than 6 cycles. . . . . ***Page 909***

RECIP and progression-free survival prediction: Gafita and colleagues identify associations between interim PSMA PET/CT by Response Evaluation Criteria in Prostate-Specific Membrane Antigen Imaging 1.0 and short-term outcomes after radiopharmaceutical treatment for metastatic prostate cancer. ***Page 917***

[177Lu]Lu-DOTATATE absorbed dose–response: Hebert and colleagues explore how postinfusion dosimetry can influence clinical management by predicting efficacy and toxicity in [177Lu]Lu-DOTATATE treatment of gastroenteropancreatic neuroendocrine tumors. . ***Page 923***

PAH for renal protection in PRRT: Moraitis and colleagues document the safety and efficacy of *para*-aminohippurate coinfusion as an alternative to amino acid coinfusion during peptide receptor radiotherapy in patients with neuroendocrine tumors. . . . . ***Page 931***

[68Ga]-FAP-2286 PET tumor dosimetry: Kline and colleagues detail the imaging characteristics of [68Ga]-FAP-2286, present dosimetry analysis, and compare the agent with [18F]-FDG and FAPI compounds. . . . . ***Page 938***

Quantitative SPECT prognosis in ATTR-CM: Caobelli and colleagues analyze the predictive and risk-stratifying value of quantitative [99mTc]Tc-DPD SPECT/CT in suspected and confirmed amyloid transthyretin–related cardiomyopathy at different disease stages. . . . . ***Page 944***

Tau PET in 4-repeat tauopathies: Bischof and colleagues report on the development and suitability of a technique for [18F]PI-2620 PET for tracking of disease progression in patients clinically diagnosed with progressive supranuclear palsy or cortical basal syndrome. . . . . ***Page 952***

Human brain [18F]VAT quantification: O'Donnell and colleagues characterize the distribution of this vesicular acetylcholine transporter–specific PET tracer in the brain and optimize methods for quantification in cholinergic pathways. . ***Page 956***

Radiomics in cervical cancer: Collarino and colleagues investigate whether radiomic features extracted from pretreatment [18F]FDG PET can improve prediction of histopathologic tumor response and survival in patients with locally advanced cervical cancer treated with neoadjuvant chemoradiotherapy and surgery. . . . . ***Page 962***

Bootstrapped kinetics of dynamic PET data: Wu and colleagues examine a nonparametric approach to mapping kinetic parameters and their uncertainties, using data from the emerging generation of dynamic whole-body PET/CT scanners. . . . .***Page 971***

DL-based PVC: Leube and colleagues introduce, test, and validate a methodology for partial volume correction of [177Lu] SPECT/CT imaging using deep learning. . . . . ***Page 980***

SSTR antagonists in Merkel cell cancer: Kircher and colleagues describe [68Ga]-labeled somatostatin receptor antagonist PET/CT imaging in a patient with metastatic Merkel cell carcinoma and discuss the potential of SSTR antagonist imaging for peptide receptor radionuclide therapy candidate selection. . . . . ***Page 988***

[18F]FES-avid irradiated lung: Rich and colleagues present a case study elucidating the nature of false-positive changes on [18F]FES PET/CT after pulmonary radiation in a patient with breast cancer and demonstrate an associated finding of [18F]FES-positive draining nodes. . . . .***Page 990***